The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases
Description of Invention:
This application describes a composition and method for treating inflammatory bowel disease or other autoimmune diseases. The composition utilizes a vector which contains a first promoter which controls the expression of a regulatory transcription factor and a second inducible promoter which controls the expression of the gene of interest. The preferred gene of interest encodes an isoform of TGF-beta such as TGF-beta1 or TGF-beta3. The isoform of TGF-beta does not have to be hTGF-beta and can be a latent or active isoform of TGF-beta. The preferred inducible promoter is TRE-CMV which can be induced using doxycycline. The usefulness of the composition for treating autoimmune diseases is demonstrated in the application in a murine model of inflammatory bowel disease in which intestinal inflammation was abrogated by the administration of a plasmid vector encoding active TGF-beta. The composition may be administered by a variety of delivery systems and intranasal delivery is exemplified.
Patent Status:
DHHS Reference No. E-096-2000/0 --
U.S. Provisional Application No. 60/199,014 filed 20 Apr 2000
PCT Application No. PCT/US01/12980 filed 20 Apr 2001, which published as WO 01/81404 on 01 Nov 2001
U.S. Patent Application No. 10/258,109 filed 30 Jun 2003
Portfolios: Internal Medicine Gene Based Therapies Cancer
Gene Based Therapies -Therapeutics-Gene Therapy-Vectors-Control sequences/genes Gene Based Therapies -Therapeutics-Gene Therapy-Vectors-Non-viral vectors Cancer -Therapeutics-Biological Response Modifiers-Cytokines Cancer -Therapeutics-Biological Response Modifiers-Growth Factors Gene Based Therapies -Therapeutics-Gene Therapy-Vectors Gene Based Therapies -Therapeutics-Gene Therapy-Therapeutic Genes Gene Based Therapies -Therapeutics-Gene Therapy-Delivery Systems Cancer -Therapeutics-Biological Response Modifiers Gene Based Therapies -Therapeutics-Gene Therapy Internal Medicine-Therapeutics-Anti-Inflammatory (including Autoimmune) Cancer -Therapeutics Gene Based Therapies -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
